COMPANY

Accipiter Biosciences

HQ: Seattle, WA source · accipiterbio.com ↗

Accipiter Biosciences designs and develops de novo protein therapies — unbound by natural limitations — to address the world’s most complex diseases. From company website Source · Oct 12, 2026

Keywords:

Location: Seattle, WA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$12.7MRaised (2 yrs)

Funding and NIH signals

SEC Form D raise Raised $10.49M (Form D filed Jul 28, 2026). SEC Form D 0001973963-26-000002 (Jul 28, 2026)
Evidence (1 event)
- Jul 28, 2026 · SEC Form D 0001973963-26-000002
  Name of Issuer: Accipiter Biosciences Inc.; CIK: 1973963; Address: Seattle, WA; Submission type: D; Filing date: 2026-07-28; Industry Group: Biotechnology; Date of First Sale: 2026-07-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10492778; Total Amount Sold: 10492778; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Nov 6, 2025 Raise Private equity round — Seed: $12.7M (total, as published), announced Nov 6, 2025. Source: company release on GlobeNewswire. source ↗

Funding

Raised: $12.7M. Last 2 years.

Nov 6, 2025 Private equity round — Seed: $12.7M (total, as published), announced Nov 6, 2025. Source: company release on GlobeNewswire. source ↗